Drugs / CH505 TF chTrimer
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06680479 | Apr 2025 → Apr 2027 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Suspended | No outcome recorded |
| Phase 1 | NCT06267872 | Oct 2024 → Dec 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 1 | NCT06205056 | Jan 2024 → Dec 2025 overdue | HIV infectious disease | U.S. Army Medical Research and Development Command | Recruiting | No outcome recorded |
| Phase 1 | NCT04915768 | Jan 2023 → Jul 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CH505 TF chTrimer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04915768 ↗ |
| Known as | CH505 TF chimeric (ch) Trimer | “HVTN 300 is a first-in-human, open-label Phase 1 study evaluating the safety and immunogenicity of a CH505 TF chimeric (ch) Trimer adjuvanted with 3M-052-AF (a TLR7/8 agonist) + Alum.” PMID 41959788 ↗ Apr 2026 |
| Modality | Vaccine | “CH505 TF chTrimer vaccine” NCT04915768 ↗ |
| Route | Intramuscular | “All products will be administered by intramuscular (IM) injection into the same quadriceps muscle at each product administration visit.” NCT06205056 ↗ |